RainDance Technologies and MLL Munich Leukemia Laboratory Collaborate on Sequence-Based Analysis of Myeloid Malignancies

Published: Jun 25, 2012

LEXINGTON, Mass. & MUNICH--(BUSINESS WIRE)--RainDance Technologies, Inc., the Digital Biologyâ„¢ Company, today announced that MLL Munich Leukemia Laboratory (MLL) has purchased the company's ThunderStormâ„¢ System and consumables to process an initial 2,000 samples for use in the identification of prognostically relevant molecular mutations associated with Acute Myeloid Leukemia (AML) and other myeloid malignancies. Additionally, RainDance and MLL announced the completion of a collaboration which has resulted in the development of a novel content panel for use in the sequence-based analysis of AML and myelodysplastic syndromes (MDS). The panel will be used at MLL and also be commercially available to RainDance customers worldwide.

Back to news